MOTS-c

Mitochondrial-derived peptide

Quick Answer

A small peptide encoded within mitochondrial DNA (rather than nuclear DNA), part of a relatively newer research category of "mitochondrial-derived peptides." Research interest here is largely academic/basic-science rather than product-driven.

Why People Are Interested

An emerging name in longevity and exercise-science circles — a mitochondrial-derived peptide with a genuinely novel proposed mechanism, exactly the kind of "what's next" science that draws early attention long before there's much human data.

What People Hope It May Do

Metabolic and exercise-adaptation benefits tied to its proposed role in mitochondrial signaling and insulin sensitivity. (Commonly discussed or proposed — not an established, evidence-backed outcome unless separately stated in Human Evidence above.)

Potential / Research Areas

How It May Work

Proposed to act as a regulator of metabolic homeostasis, with hypothesized roles in insulin sensitivity and exercise-related metabolic adaptation — based on early-stage animal and cell research; considered a hypothesis under investigation, not established human physiology.

What Human Research Shows

Minimal. This compound is at a substantially earlier research stage than most others in this database — largely basic science and animal research, with very limited human data.

What Preclinical Research Shows

The primary evidence base — rodent metabolic studies and cell-culture research.

What People Report

What Experts Are Saying

Curated commentary specific to MOTS-c is planned as the Expert & Creator Library grows. Being listed there does not imply an expert's endorsement of Element Health Labs.

Clinical Trials

For the current, authoritative list of registered trials involving MOTS-c, search ClinicalTrials.gov directly — trial status changes frequently, and that registry is the source of truth, not a static summary on this page.

Potential Risks & Side Effects

No meaningful human safety data exists publicly. This should be stated plainly rather than speculated about.

Regulatory Status

Not FDA-approved. Not in human clinical development at the scale of an approved-product pathway as of last review; treat any claims of clinical trials with particular skepticism and verify directly at clinicaltrials.gov.

Recent development (2026-08-17): On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee voted 7-5 (2 abstentions) to recommend adding MOTS-c to the FDA's 503A Bulks List, which would let compounding pharmacies legally use it. This is a nonbinding advisory recommendation only — the FDA has not added MOTS-c to that list, nothing about its legal status has actually changed, and it remains not FDA-approved. The FDA must still decide whether to proceed through formal notice-and-comment rulemaking. Worth noting for context: the agency's own scientists reportedly opposed the recommendation, and a majority of the panelists who voted yes reportedly have ties to the peptide industry. Full sourcing in This Week in Peptides.

What We Still Don't Know

Nearly everything about human dosing, safety, and whether the animal-model metabolic signals hold up in people at all — this is genuinely early-stage science.

Limitations of Evidence

Very early-stage basic science; discussion of this compound in consumer content should be framed clearly as "an area of early scientific interest," not as something with established effects in humans.

Keep Researching

• Search ClinicalTrials.gov for MOTS-c
• Expert & Creator Library
• This Week in Peptides
• Understanding Your Bloodwork
• Related peptides:
  • Kpv
  • Epitalon